Because our hypothesis is that TERT gene disruption may offer a universal approach to treat cancer, we selected three different cancer cell lines to evaluate the efficiencies of these gRNAs: a cervical cancer cell line Hela, a pancreatic cancer cell line PANC1, and a breast cancer cell line SUM159. The gene discussed is TERT; the disease is breast carcinoma.